07:00 , Sep 28, 2009 |  BC Week In Review  |  Company News

BurnsAdler, Three Rivers sales and marketing update

Three Rivers granted BurnsAdler exclusive rights to market Infergen interferon alphacon-1 in Brazil and Chile to treat HCV. Three Rivers has rights to the drug in the U.S. and Canada from Valeant Pharmaceuticals International (NYSE:VRX,...
07:00 , Aug 7, 2006 |  BC Week In Review  |  Company News

Innocoll, BurnsAdler sales and marketing update

Innocoll's Innocoll Pharmaceuticals Ltd. unit granted BurnsAdler rights to distribute CollaRx gentamicin surgical implant to treat and prevent postoperative infections in Mexico, Argentina, Chile, Colombia and selected Caribbean islands. Innocoll has rights to the product...